Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58, 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Aydin H, Zhou M. The changing face of renal cell carcinoma pathology. Curr. Oncol. Rep.10, 235–244 (2008).
   PubMedGoogle Scholar
• Surveillance Epidemiology and End Results SEER Stat Fact Sheets (2008).
   Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-carcinoma. N. Engl. J. Med.256(2), 125–134 (2007).
   Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370, 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349, 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26, 5422–5428 (2008).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356, 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372, 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol.8, 975–984 (2007).
   PubMed Web of Science ®Google Scholar
• Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(9), 1432–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol.9, 117–123 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol.48(1), 9–17 (2009).
   PubMed Web of Science ®Google Scholar
• Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis.49, 186–193 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Schiller JH, Freuhauf J et al. Association of diastolic blood pressure ≥ 90 mmHg with overall survival in patients treated with axitinib (AG-013736). J. Clin. Oncol.26 (2008) (Abstract 3543).
   Google Scholar
• Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet370, 2011–2019 (2007).
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer7, 332–344 (2007).
   PubMed Web of Science ®Google Scholar
• Khakoo AY, Kassiotis CM, Tannir N et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer112, 2500–2508 (2008).
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.26, 5204–5212 (2008).
   PubMed Web of Science ®Google Scholar
• Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann. Oncol.19, 1613–1618 (2008).
   PubMed Web of Science ®Google Scholar
• Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation110, 718–723 (2004).
   PubMedGoogle Scholar
• Hubner N, Yagil C, Yagil Y. Novel integrative approaches to the identification of candidate genes in hypertension. Hypertension47, 1–5 (2006).
   PubMedGoogle Scholar
• Shiojima I, Sato K, Izumiya Y et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest.115, 2108–2118 (2005).
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Watanabe T, Nishida K et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J. Clin. Invest.114, 937–943 (2004).
   PubMed Web of Science ®Google Scholar
• Kido M, Du L, Sullivan CC et al. Hypoxia-inducible factor 1-α reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J. Am. Coll. Cardiol.46, 2116–2124 (2005).
   PubMed Web of Science ®Google Scholar
• Parisi Q, Biondi-Zoccai GG, Abbate A et al. Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. Int. J. Cardiol.99, 337–339 (2005).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) wih FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21, 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for mestatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-anaysis. JAMA300, 227–2285 (2008).
   Google Scholar
• Desai J, Yassa L, Marqusee E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann. Intern. Med.145, 660–664 (2006).
   PubMed Web of Science ®Google Scholar
• Faris JE, Moore AF, Daniels GH. Sunitinib (Sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid17, 1147–1149 (2007).
   PubMed Web of Science ®Google Scholar
• Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin. Endocrinol. (Oxf.)69, 669–672 (2008).
   PubMed Web of Science ®Google Scholar
• Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst.99, 81–83 (2007).
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Bukowski R, Elson P et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol.19, 265–268 (2008).
   PubMed Web of Science ®Google Scholar
• Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int. J. Exp. Pathol.88, 271–277 (2007).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22, 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24, 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC Jr, Chaudhary UB. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist12, 1178–1182 (2007).
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann. Oncol.19(11), 1955–1961 (2008).
   PubMed Web of Science ®Google Scholar
• Lai SE, Kuzel T, Lacouture ME. Hand–foot and stump syndrome to sorafenib. J. Clin. Oncol.25, 341–343 (2007).
   PubMedGoogle Scholar
• Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW. Hand–foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J. Clin. Oncol.24, 5786–5788 (2006).
   PubMedGoogle Scholar
• Yang CH, Lin WC, Chuang CK et al. Hand–foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br. J. Dermatol.158, 592–596 (2008).
   PubMed Web of Science ®Google Scholar
• Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol.6, 491–500 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support. Care Cancer16, 557–566 (2008).
   PubMed Web of Science ®Google Scholar
• Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand–foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol.47, 176–186 (2008).
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin. Exp. Med.7, 127–134 (2007).
   PubMed Web of Science ®Google Scholar
• Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. N. Engl. J. Med.334, 494–500 (1996).
   PubMed Web of Science ®Google Scholar
• Cumurciuc R, Martinez-Almoyna L, Henry C, Husson H, de Broucker T. Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev. Neurol. (Paris)164, 605–607 (2008).
   PubMed Web of Science ®Google Scholar
• Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med.354, 980–982 (2006).
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J. Clin. Oncol.24, e48 (2006).
   Google Scholar
• Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann. Oncol.18, 1745–1747 (2007).
   PubMedGoogle Scholar
• Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J. Clin. Oncol.25, 3559 (2007).
   PubMed Web of Science ®Google Scholar
• Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med.354, 980–982 (2006).
   PubMedGoogle Scholar
• Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr. Clin. Pharmacol.3, 132–143 (2008).
   PubMedGoogle Scholar
• Billemont B, Izzedine H, Rixe O. Macrocytosis due to treatment with sunitinib. N. Engl. J. Med.357, 1351–1352; author reply 1352 (2007).
   PubMed Web of Science ®Google Scholar
• Gillessen S, Graf L, Korte W, Cerny T. Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N. Engl. J. Med.356, 2330–2331 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Choueiri TK, Elson P et al. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer113, 1309–1314 (2008).
   PubMedGoogle Scholar
• Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest. New Drugs27(1), 83–87 (2009).
   PubMed Web of Science ®Google Scholar
• Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann. Surg. Oncol.14, 1860–1869 (2007).
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.23, 792–799 (2005).
   PubMed Web of Science ®Google Scholar
• Torisel®, package insert. Wyeth Pharmaceuticals, Inc., PA, USA (2008).
   Google Scholar
• Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann. Oncol.14, 931–937 (2003).
   PubMed Web of Science ®Google Scholar
• Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ. Bowel perforation after radiotherapy in a patient receiving sorafenib. J. Clin. Oncol.26, 2405–2406 (2008).
   PubMed Web of Science ®Google Scholar
• Grunwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie30, 519–524 (2007).
   PubMedGoogle Scholar
• Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist13, 1084–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can. Urol. Assoc. J.1, S41–S54 (2007).
   Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Sutent®, package insert. Pfizer Inc., NY, USA (2008).
   Google Scholar
• Nexavar®, package insert. Bayer Healthcare Pharmaceuticals Inc., NJ, USA (2009).
   Google Scholar
• Avastin®, package insert. Genentech, CA, USA (2008).
   Google Scholar
• Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand–foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist13, 1001–1011 (2008).
   PubMed Web of Science ®Google Scholar
• Dutcher JP, Wilding G, Hudes GR et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J. Clin. Oncol.26, (2008) (Abstract 5127).
   Google Scholar
• Choueiri TK, Vaziri SA, Jaeger E et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol.180, 860–865 (2008).
   PubMed Web of Science ®Google Scholar
• Faber PW, Vaziri SA, Wood L et al. Potential non-synonymous single nucleotide polymorphism (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib. J. Clin. Oncol.26 (2008) (Abstract 5009).
   Google Scholar
• Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin. Cancer Res.13, 1098–1106 (2007).
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Serova M, Raymond E. mTORCI inhibitors: is temsirolimus in renal cancer telling us how they really work? Br. J. Cancer99, 1197–1203 (2008).
   PubMed Web of Science ®Google Scholar